Telix begins Phase 1 trial of TLX090, a new radiopharmaceutical for bone cancer pain, showing early promise for safe, long-lasting relief.

Telix Pharmaceuticals has begun dosing patients in the SOLACE Phase 1 trial for TLX090 (153Samarium-DOTMP), a new radiopharmaceutical targeting pain from bone metastases in advanced cancer. The trial will enroll up to 33 patients to evaluate safety, dosing, and pain relief. TLX090 aims to deliver targeted radiation to bone tumors while sparing healthy tissue, offering a potential non-opioid, systemic treatment with a single dose that may relieve pain for 3–4 months. Early data suggest a favorable safety profile and promising effectiveness. The drug’s cold-kit formulation and pharmacy-based distribution could improve access. The trial, conducted with Oncology Consultants in Houston, may support a streamlined regulatory path. TLX090 remains investigational and has not been approved anywhere.